Comparing Mind Medicine (MindMed) (NASDAQ:MNMD) & Pervasip (OTCMKTS:PVSP)

Mind Medicine (MindMed) (NASDAQ:MNMD) and Pervasip (OTCMKTS:PVSP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Profitability

This table compares Mind Medicine (MindMed) and Pervasip’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mind Medicine (MindMed)	N/A	-84.72%	-59.00%
Pervasip	-14.89%	N/A	-26.25%

Analyst Ratings

This is a breakdown of current ratings for Mind Medicine (MindMed) and Pervasip, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mind Medicine (MindMed)	0	0	7	0	3.00
Pervasip	0	0	0	0	N/A

Mind Medicine (MindMed) currently has a consensus price target of $17.67, suggesting a potential upside of 122.22%. Given Mind Medicine (MindMed)’s higher possible upside, research analysts clearly believe Mind Medicine (MindMed) is more favorable than Pervasip.

Risk & Volatility

Mind Medicine (MindMed) has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500. Comparatively, Pervasip has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Earnings & Valuation

This table compares Mind Medicine (MindMed) and Pervasip’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mind Medicine (MindMed)	N/A	N/A	-$95.73 million	($2.94)	-2.70
Pervasip	$15.77 million	0.12	-$2.35 million	N/A	N/A

Pervasip has higher revenue and earnings than Mind Medicine (MindMed).

Institutional & Insider Ownership

27.9% of Mind Medicine (MindMed) shares are held by institutional investors. 2.3% of Mind Medicine (MindMed) shares are held by insiders. Comparatively, 9.2% of Pervasip shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

About Pervasip

Pervasip Corporation focuses on developing cloud-based applications to monitor and control greenhouse facilities. It intends to develop and deliver products and technologies to agricultural markets; develop scientific methods for the analysis of cannabinoids in flowers, concentrates, and edibles; and assist medical marijuana specialty production facilities to regulate, calculate proper dosage, and understand the importance of consistency in product. The company was formerly known as eLEC Communications Corp. and changed its name to Pervasip Corp. in December 2007. Pervasip Corp. was founded in 1964 and is based in White Plains, New York.